00936nam0-22002891i-450-99000744212040332120030530000744212FED01000744212(Aleph)000744212FED0100074421220030530d1963----km-y0itay50------bagerDEy-------001yyStudien zum internationalen WirtschaftsrechtGrundlegung, Gatt, Marktstörung, Dumping, Subvention, Investitionsschutzvon Eugen LangenMünchenBeck1963VIII, 131 p.24 cmSchriften des Instituts für Wirtschaftsrecht an der Universität Köln17Langen,Eugen247211ITUNINARICAUNIMARCBK990007442120403321UNIVERSITÀ 142 (17)75008FGBCFGBCStudien zum internationalen Wirtschaftsrecht678598UNINA01245cam0 22003251 450 SOBE0006529520210125092011.0978884309604620210125d2019 |||||ita|0103 baitaITArcheologia dei medianuove prospettive per la storia e la teoria della comunicazioneJussi Parikkaprefazione di Ruggero Eugenipostfazione di Simone VenturiniRomaCarocci2019282 p.ill.22 cmStudi superiori1191Traduzione di Enrico Campo e Simone Dotto001SOBE000168012001 *Studi superiori1191What is media archaelogy?SOBA000206631765053Parikka, JussiSOBA00020660070772265Eugeni, RuggeroAF00004906070Venturini, Simone <1972->SOBA00020661070ITUNISOB20210125RICAUNISOBUNISOB300173900SOBE00065295M 102 Monografia moderna SBNM300005138SI17390020210118acquistoVmenleUNISOBUNISOB20210125091928.020210125092011.0menleWhat is media archaelogy1765053UNISOB05363nam 2200649Ia 450 991082990450332120170816122630.01-280-72281-997866107228153-527-60876-13-527-60860-5(CKB)1000000000376655(EBL)481418(SSID)ssj0000157791(PQKBManifestationID)11149262(PQKBTitleCode)TC0000157791(PQKBWorkID)10139905(PQKB)10093951(MiAaPQ)EBC481418(OCoLC)85821120(EXLCZ)99100000000037665520060111d2006 uy 0engur|n|---|||||txtccrFragment-based approaches in drug discovery[electronic resource] /edited by Wolfgang Jahnke and Daniel A. ErlansonWeinheim Wiley-VCH ;[Chichester John Wiley, distributor]c20061 online resource (393 p.)Methods and principles in medicinal chemistry ;34Description based upon print version of record.3-527-31291-9 Includes bibliographical references and index.Fragment-based Approaches in Drug Discovery; Contents; Preface; A Personal Foreword; List of Contributors; Part I: Concept and Theory; 1 The Concept of Fragment-based Drug Discovery; 1.1 Introduction; 1.2 Starting Small: Key Features of Fragment-based Ligand Design; 1.2.1 FBS Samples Higher Chemical Diversity; 1.2.2 FBS Leads to Higher Hit Rates; 1.2.3 FBS Leads to Higher Ligand Efficiency; 1.3 Historical Development; 1.4 Scope and Overview of this Book; References; 2 Multivalency in Ligand Design; 2.1 Introduction and Overview; 2.2 Definitions of Terms2.3 Selection of Key Experimental Studies2.3.1 Trivalency in a Structurally Simple System; 2.3.2 Cooperativity (and the Role of Enthalpy) in the "Chelate Effect"; 2.3.3 Oligovalency in the Design of Inhibitors to Toxins; 2.3.4 Bivalency at Well Defined Surfaces (Self-assembled Monolayers, SAMs); 2.3.5 Polyvalency at Surfaces of Viruses, Bacteria, and SAMs; 2.4 Theoretical Considerations in Multivalency; 2.4.1 Survey of Thermodynamics; 2.4.2 Additivity and Multivalency; 2.4.3 Avidity and Effective Concentration (C(eff)); 2.4.4 Cooperativity is Distinct from Multivalency2.4.5 Conformational Entropy of the Linker between Ligands2.4.6 Enthalpy/Entropy Compensation Reduces the Benefit of Multivalency; 2.5 Representative Experimental Studies; 2.5.1 Experimental Techniques Used to Examine Multivalent Systems; 2.5.1.1 Isothermal Titration Calorimetry; 2.5.1.2 Surface Plasmon Resonance Spectroscopy; 2.5.1.3 Surface Assays Using Purified Components (Cell-free Assays); 2.5.1.4 Cell-based Surface Assays; 2.5.2 Examination of Experimental Studies in the Context of Theory; 2.5.2.1 Trivalency in Structurally Simple Systems2.5.2.2 Cooperativity (and the Role of Enthalpy) in the "Chelate Effect"2.5.2.3 Oligovalency in the Design of Inhibitors of Toxins; 2.5.2.4 Bivalency in Solution and at Well Defined Surfaces (SAMs); 2.5.2.5 Polyvalency at Surfaces (Viruses, Bacteria, and SAMs); 2.6 Design Rules for Multivalent Ligands; 2.6.1 When Will Multivalency Be a Successful Strategy to Design Tight-binding Ligands?; 2.6.2 Choice of Scaffold for Multivalent Ligands; 2.6.2.1 Scaffolds for Oligovalent Ligands; 2.6.2.2 Scaffolds for Polyvalent Ligands; 2.6.3 Choice of Linker for Multivalent Ligands2.6.3.1 Rigid Linkers Represent a Simple Approach to Optimize Affinity2.6.3.2 Flexible Linkers Represent an Alternative Approach to Rigid Linkers to Optimize Affinity; 2.6.4 Strategy for the Synthesis of Multivalent Ligands; 2.6.4.1 Polyvalent Ligands: Polymerization of Ligand Monomers; 2.6.4.2 Polyvalent Ligands: Functionalization with Ligands after Polymerization; 2.7 Extensions of Multivalency to Lead Discovery; 2.7.1 Hetero-oligovalency Is a Broadly Applicable Concept in Ligand Design; 2.7.2 Dendrimers Present Opportunities for Multivalent Presentation of Ligands2.7.3 Bivalency in the Immune SystemThis first systematic summary of the impact of fragment-based approaches on the drug development process provides essential information that was previously unavailable. Adopting a practice-oriented approach, this represents a book by professionals for professionals, tailor-made for drug developers in the pharma and biotech sector who need to keep up-to-date on the latest technologies and strategies in pharmaceutical ligand design. The book is clearly divided into three sections on ligand design, spectroscopic techniques, and screening and drug discovery, backed by numerous case studies.Methods and principles in medicinal chemistry ;v. 34.Drug developmentLigands (Biochemistry)Drug development.Ligands (Biochemistry)615615.1901Jahnke Wolfgang1707025Erlanson Daniel A1707026MiAaPQMiAaPQMiAaPQBOOK9910829904503321Fragment-based approaches in drug discovery4094909UNINA